AU2001249284A1 - L-arginine and phosphodiesterase (pde) inhibitor synergism - Google Patents

L-arginine and phosphodiesterase (pde) inhibitor synergism

Info

Publication number
AU2001249284A1
AU2001249284A1 AU2001249284A AU4928401A AU2001249284A1 AU 2001249284 A1 AU2001249284 A1 AU 2001249284A1 AU 2001249284 A AU2001249284 A AU 2001249284A AU 4928401 A AU4928401 A AU 4928401A AU 2001249284 A1 AU2001249284 A1 AU 2001249284A1
Authority
AU
Australia
Prior art keywords
pde
phosphodiesterase
arginine
synergism
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001249284A
Inventor
Arthur W Wallace
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of AU2001249284A1 publication Critical patent/AU2001249284A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
AU2001249284A 2000-03-23 2001-03-19 L-arginine and phosphodiesterase (pde) inhibitor synergism Abandoned AU2001249284A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/644,982 US6476037B1 (en) 2000-03-23 2000-03-23 L-arginine and phosphodiesterase (PDE) inhibitor synergism
US09/644,982 2000-03-23
PCT/US2001/008863 WO2001070211A2 (en) 2000-03-23 2001-03-19 L-arginine and phosphodiesterase (pde) inhibitor synergism

Publications (1)

Publication Number Publication Date
AU2001249284A1 true AU2001249284A1 (en) 2001-10-03

Family

ID=24587162

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001249284A Abandoned AU2001249284A1 (en) 2000-03-23 2001-03-19 L-arginine and phosphodiesterase (pde) inhibitor synergism

Country Status (3)

Country Link
US (2) US6476037B1 (en)
AU (1) AU2001249284A1 (en)
WO (1) WO2001070211A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
GR1002847B (en) 1997-05-06 1998-01-27 Use of micropostol and/or micropostol acid for the preparation of a medicine for the therapeutic treatiment of problems related to the erection
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
GR1003199B (en) 1998-08-14 1999-09-01 Use of micropostol and/or micropostol acid for the preparation of a medicine for the therapeutic threatment of problemes related to the female sexual malfunction
DE10010612A1 (en) * 2000-03-03 2001-09-27 Merck Patent Gmbh Treatment of erectile dysfunction without inducing circulatory side-effects, using penis-specific phosphodiesterase V inhibitors, preferably benzo (4,5) thieno (2,3-d) pyrimidine derivatives
US7737147B2 (en) * 2000-07-27 2010-06-15 Thomas Nadackal Thomas Methods and compositions to enhance the efficacy of phosphodiesterase inhibitors
US7128930B1 (en) * 2000-09-01 2006-10-31 Meir S. Sacks Compositions and methods for treating sexual dysfunction
GB0125222D0 (en) * 2001-10-19 2001-12-12 Barts & London Nhs Trust Composition for the treatment of microbial infections
US20020182162A1 (en) * 2002-08-07 2002-12-05 Mohsen Shahinpoor Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for enhanced hair growth
JP2006512369A (en) * 2002-12-19 2006-04-13 サイオス・インコーポレーテツド Treatment of obesity and related symptoms with TGF-β inhibitors
US7214390B2 (en) * 2003-02-07 2007-05-08 Barmensen Labs, Llc Topical compositions for enhancing sexual responsiveness
DE10325813B4 (en) * 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxis and / or therapy in portal hypertension
ATE372777T1 (en) * 2003-07-09 2007-09-15 Us Gov Health & Human Serv USE OF NITRITE SALTS TO TREAT CARDIOVASCULAR DISEASES
DE10352511A1 (en) * 2003-11-07 2005-06-16 Ernst-Moritz-Arndt-Universität Greifswald Use of MRP4 inhibitors for the treatment and / or prophylaxis of cardiovascular diseases
US20050163759A1 (en) * 2003-11-26 2005-07-28 Geliebter David M. Compositions and methods for ex vivo preservation of blood vessels for vascular grafts using inhibitors of type I and/or type II phosphodiesterases
US20050169894A1 (en) * 2003-11-26 2005-08-04 Geliebter David M. Compositions and methods for ex vivo preservation of blood vessels for vascular grafts using inhibitors of Type III and/or Type IV phosphodiesterases
US20050282751A1 (en) * 2004-03-19 2005-12-22 Ajinomoto Co., Inc. Therapeutic agent for renal anemia
US7362274B1 (en) * 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
US8557300B2 (en) * 2005-05-19 2013-10-15 University Of Cincinnati Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
EP2114876A4 (en) * 2007-02-05 2010-12-22 Amira Pharmaceuticals Inc Reverse indoles as 5-lipoxygenase-activating protein (flap) inhibitors
WO2010068311A1 (en) 2008-05-23 2010-06-17 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein inhibitor
US20140271847A1 (en) * 2013-03-13 2014-09-18 SatisPharma, LLC Formulations and methods for rapid penile erections
US20180078602A1 (en) * 2015-03-04 2018-03-22 K.L.R.M., Llc Methods and compositions for extending the efficacy of phosphodiesterase inhibitors for treating erectile dysfunction, and compositions for inhibiting the onset and slowing the progression of erectile dysfunction
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891459A (en) * 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
US5543430A (en) * 1994-10-05 1996-08-06 Kaesemeyer; W. H. Method and formulation of stimulating nitric oxide synthesis
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
CA2270118A1 (en) 1996-11-01 1998-05-14 Nitromed Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US5958926A (en) * 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
EP0998274B1 (en) 1997-06-23 2006-01-18 Cellegy Pharmaceuticals, Inc Microdose therapy of vascular conditions by no donors
US6207713B1 (en) * 1997-09-17 2001-03-27 Eric T. Fossel Topical and oral delivery of arginine to cause beneficial effects
US6127363A (en) 1997-10-28 2000-10-03 Vivus, Inc. Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction
US5919474A (en) 1997-10-28 1999-07-06 Vivus, Inc. Transurethral administration of vasoactive agents to treat peripheral vascular disease, related vascular diseases, and vascular impotence associated therewith
US6156753A (en) 1997-10-28 2000-12-05 Vivus, Inc. Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6071272A (en) * 1997-10-28 2000-06-06 Hoffman; Alan S. Method for treating erectile dysfunctionality
WO1999051252A1 (en) 1998-04-03 1999-10-14 The Daily Wellness Company Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation
US6277884B1 (en) * 1998-06-01 2001-08-21 Nitromed, Inc. Treatment of sexual dysfunction with N-hydroxyguanidine compounds
AU4699299A (en) 1998-06-26 2000-01-17 Nutracorp Scientific, Inc. Promoting nitric oxide and cyclic gmp activity
US6284763B1 (en) * 1998-08-26 2001-09-04 Queen's University At Kingston Methods for remodeling neuronal and cardiovascular pathways
US6482426B1 (en) 1998-09-17 2002-11-19 Zonagen, Inc. Compositions for the treatment of male erectile dysfunction

Also Published As

Publication number Publication date
US20030166661A1 (en) 2003-09-04
WO2001070211A2 (en) 2001-09-27
US6476037B1 (en) 2002-11-05
WO2001070211A3 (en) 2002-08-08

Similar Documents

Publication Publication Date Title
AU2001249284A1 (en) L-arginine and phosphodiesterase (pde) inhibitor synergism
AU7392101A (en) 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
AU2001244355A1 (en) Heterobiarylsulphonamides and their use as pde 7 inhibitors
AU2001258771A1 (en) -secretase inhibitors
AU2001249969A1 (en) Inha inhibitors and their use as antibacterials
AU2001240542A1 (en) Heterocyclic compounds and their use as parp inhibitors
AU2001265008A1 (en) Caspase inhibitors and uses thereof
AU2002211663A1 (en) Nf-$g(k)b inhibitors
GB0025782D0 (en) Use of inhibitors
AU6117801A (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
AU2002220241A1 (en) Parb inhibitors
AU2002227985A1 (en) Pyrrolo (2.1-a) dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors
AU2002230836A1 (en) Benzylamine derivatives and their use as thrombin inhibitors
AU4217201A (en) Tri-aryl-substituted-ethane pde4 inhibitors
AU2002248269A1 (en) Use of p38 inhibitors for the treatment of inflammation-enhanced cough
AU2001286242A1 (en) Urea derivative and adhesive-molecule inhibitor containing the same as active ingredient
AU2001244596A1 (en) Indolylpyrrole derivatives and cell death inhibitors
PL361733A1 (en) Sulfamidothienopyrimidines and the use of the same as phosphodiesterase v inhibitors
AU2002216650A1 (en) Triazine derivatives as lpaat-b inhibitors and uses thereof
AU2002241211A1 (en) Imidazo-triazine derivatives as pde 5 inhibitors
AU2001293048A1 (en) Antiviral compositions and methods of use
AU2001232809A1 (en) Gyrase inhibitors and uses thereof
AU2001266124A1 (en) 2-aminothiazoline derivatives and their use as no-synthase inhibitors
AU1039801A (en) Compounds and their use as cysteine protease inhibitors
AU2001268236A1 (en) Use of aicar and related compounds